At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Akt inhibitor MK2206drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Akt inhibitor MK2206 for Recurrent Squamous Cell Carcinoma of the Nasopharynx and Stage IV Squamous Cell Carcinoma of the Nasopharynx. Completed, enrolled 21 participants across 8 sites in 3 countries.
Detailed Summary
This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with recurrent or metastatic head and neck cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx
CountriesChina, Singapore, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedMay 2011
Primary CompletionOct 2013
TodayJul 2026
First PostedMay 9, 2011
Enrollment StartApr 1, 2011
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.1 years ago
Interventions
Akt inhibitor MK2206drug
Given PO